KR900012612A - 제약 조성물 - Google Patents

제약 조성물 Download PDF

Info

Publication number
KR900012612A
KR900012612A KR1019900002250A KR900002250A KR900012612A KR 900012612 A KR900012612 A KR 900012612A KR 1019900002250 A KR1019900002250 A KR 1019900002250A KR 900002250 A KR900002250 A KR 900002250A KR 900012612 A KR900012612 A KR 900012612A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
ranitidine
filler
mixture
weight
Prior art date
Application number
KR1019900002250A
Other languages
English (en)
Other versions
KR940006271B1 (ko
Inventor
쿠마 코르라 샴
트리브호반 마카디아 태런
Original Assignee
데이빗 에이. 브라운
글락소 캐나다 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데이빗 에이. 브라운, 글락소 캐나다 인크. filed Critical 데이빗 에이. 브라운
Publication of KR900012612A publication Critical patent/KR900012612A/ko
Application granted granted Critical
Publication of KR940006271B1 publication Critical patent/KR940006271B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

제약 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 적어도 1종의 지방산 글리세리드 및(또는) 광유 또는 파라핀으로된 비수용성 매트릭스를 기재로 하는 충전제와 유효성분으로서 라니티딘 또는 생리학상 허용되는 그의 염을 함유하고, 젤라틴 외피에 의해 둘러싸인 젤라틴 캡슐 형태의 제약조성물.
  2. 제1항에 있어서, 매트릭스가 적어도 1종의 계면활성제를 함유하는 제약조성물.
  3. 제2항에 있어서, 매트릭스가 지방산 글리세리드 및(또는) 광유 또는 파라핀의 혼합물로 되고 이 혼합물중 적어도 1종의 성분은 계면활성의 특성을 갖는 제약조성물.
  4. 제2항에 있어서, 계면활성제가 레시틴인 제약조성물.
  5. 중간 길이의 사슬을 갖는 지방산 글리세리드의 혼합물인 제1유성 부형제와, 긴 사슬을 갖는 지방산 글리세리 생리학상 허용되는 그 염을 함유하고, 젤라틴 외피에 의해 둘러싸인 젤라틴 캡슐 형태의 제약조성물.
  6. 제5항에 있어서, 제1유성 부형제가 C5-C10지방산의 트리글리세리드의 혼합물이고, 제2유성부형제가 C12-C18지방산의 모노-, 디- 및(또는) 트리글리세리드의 혼합물인 제약조성물.
  7. 제5항에 있어서, 제1유성부형제가 전체충전제의 20 내지 60중량%를 구성하고, 제2유성부형제가 전체 충전제의 5 내지 35중량%를 구성하는 제약조성물.
  8. 제1항 내지 제7항중 어느 하나의 항에 있어서, 젤라틴 외피가 연질 젤라틴 외피인 제약조성물.
  9. 제1항 내지 제8항중 어느 하나의 항에 있어서, 라니티딘의 라니티딘 염산염 형태로 사용되는 제약 조성물.
  10. 제1항 내지 제9항중 어느 하나의 항에 있어서, 충전제의 라니티딘(유리 염기 형태이거나 또는 생리학상 허용되는 그의 염 형태임)함량이 30 내지 70중량%인 제약 조성물.
  11. C8-C10지방산의 트리글리세리드의 혼합물이며 전체 충전제의 30 내지 40중량%를 구성하고 있는 제1유성 부형제와, C12-C18지방산의 모노-디-및(또는) 트리글리세리드의 혼합물이고 전체충전제의 20 내지 25중량%를 구성하고 있는 제2유성 부형제로 이루어진 비수용성 매트릭스를 기재로 하는 충전제와 유효성분으로서 라니티딘 염산염을 함유하며, 라니티딘 염산염이 충전제의 45내지 55중량%를 구성하는 젤라틴 캡슐 형태의 제약 조성물.
  12. 젤라틴 캡슐용 충전제로서 사용하기 적합하고, 적어도 1종의 지방산 글리세리드 및(또는) 광유 또는 파라핀으로된 비수용성 매트릭스와, 라니티딘 또는 생리학상 허용되는 그의 염으로 이루어진 제약 조성물.
  13. 제약 허용되는 비수용성 담체와 함께, 적어도 1종의 지방산 글리세리드 및(또는) 광유 또는 파라핀으로된 비수용성 매트릭스와, 라니티딘 또는 생리학상 허용되는 그의 염으로된 비수용성 제약 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900002250A 1989-02-23 1990-02-22 제약 조성물 KR940006271B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898904182A GB8904182D0 (en) 1989-02-23 1989-02-23 Pharmaceutical compositions
GB8904182.6 1989-02-23
GB89-04182.6 1989-02-23

Publications (2)

Publication Number Publication Date
KR900012612A true KR900012612A (ko) 1990-09-01
KR940006271B1 KR940006271B1 (ko) 1994-07-14

Family

ID=10652220

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900002250A KR940006271B1 (ko) 1989-02-23 1990-02-22 제약 조성물

Country Status (26)

Country Link
US (1) US5028432A (ko)
JP (1) JP2856817B2 (ko)
KR (1) KR940006271B1 (ko)
AT (1) AT401727B (ko)
AU (1) AU629303B2 (ko)
BE (1) BE1003123A3 (ko)
CA (1) CA2010692C (ko)
CH (1) CH680567A5 (ko)
CY (1) CY1734A (ko)
DE (1) DE4005650C2 (ko)
DK (1) DK170209B1 (ko)
FR (1) FR2643263B1 (ko)
GB (2) GB8904182D0 (ko)
HK (1) HK89493A (ko)
HU (1) HU211930A9 (ko)
IE (1) IE63179B1 (ko)
IL (1) IL93490A (ko)
IT (1) IT1240768B (ko)
LU (1) LU87681A1 (ko)
NL (1) NL193267C (ko)
NZ (1) NZ232642A (ko)
PH (1) PH26972A (ko)
SA (1) SA90100287B1 (ko)
SE (1) SE512412C2 (ko)
ZA (1) ZA901348B (ko)
ZW (1) ZW1790A1 (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004893A1 (en) * 1990-09-13 1992-04-02 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
US5571533A (en) * 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
DE69313865T2 (de) * 1992-10-16 1998-02-12 Glaxo Group Ltd Geschmacksmaskierende zusammensetzungen von ranitidin
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
DE4341310A1 (de) * 1993-12-03 1995-06-08 Hexal Pharma Gmbh Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
GB9705813D0 (en) * 1997-03-20 1997-05-07 Smithkline Beecham Plc Novel compositions
AR013261A1 (es) * 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
JP2005531495A (ja) * 2001-12-21 2005-10-20 シャイア ラボラトリーズ，インコーポレイテッド 高い物理的安定性を有する経口カプセル製剤
WO2004069180A2 (en) * 2003-01-31 2004-08-19 Smithkline Beecham Corporation Solid dispersion compositions
DK1660047T3 (en) 2003-08-13 2014-03-10 Biocon Ltd MICROPARTICALLY FATIC ACID SALT SOLID DOSAGE FORMS FOR THERAPEUTIC AGENTS
ES2529216T3 (es) 2010-06-23 2015-02-18 Colgate-Palmolive Company Composición oral terapéutica
EP2654671B1 (en) 2010-12-20 2019-02-20 Colgate-Palmolive Company Non-aqueous oral care composition containing dental occlusion actives
CN103260586B (zh) 2010-12-20 2016-03-02 高露洁-棕榄公司 明胶包封的包含牙齿封闭活性物、疏水性粘度调节剂和油性载体的口腔护理组合物
WO2012087280A2 (en) 2010-12-20 2012-06-28 Colgate-Palmolive Company Gelatin encapsulated oral care composition containing hydrophilic active, hydrophobic structuring agent and oil carrier
AU2017353968B2 (en) * 2016-11-01 2023-02-02 Johnson & Johnson Consumer Inc. Liquid oral pharmaceutical dosage form comprising an histamine H2-receptor antagonist and an antacid
CN109010303B (zh) * 2017-06-09 2021-05-07 苏州科伦药物研究有限公司 一种盐酸雷尼替丁胶囊的工业制备方法
KR102108153B1 (ko) * 2017-07-05 2020-05-07 (주)동구바이오제약 생체 이용률 및 안정성이 개선된 레티노이드를 함유하는 약제학적 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3374146A (en) * 1966-04-18 1968-03-19 American Cyanamid Co Sustained release encapsulation
DE2360796B2 (de) * 1973-12-06 1977-06-02 Edelfettwerke Werner Schlüter, 2000 Hamburg; Glyco Iberica S.A., Gava, Barcelona (Spanien) Vti: Hegel, K.Th., Dr.; Dickel, K., Dipl.-Ing.; Pat.-Anwälte, 2000 Hamburg und 8000 München Arzneimittel mit verzoegerter abgabe des wirkstoffs im darm
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
IT1090703B (it) * 1976-12-03 1985-06-26 Scherer Ltd R P Perfezionamento nelle composizioni utili quali veicolo per farmaci
JPS5919524B2 (ja) * 1976-12-17 1984-05-07 中外製薬株式会社 安定な１α−ヒドロキシビタミンＤ類含有製剤
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
JPS55136219A (en) * 1979-04-11 1980-10-23 Sumitomo Chem Co Ltd Diazepam oily drug
EP0040489A1 (en) * 1980-05-17 1981-11-25 FISONS plc Mixtures, salts, packages and pharmaceutical compositions containing 5-(2-hydroxypropoxy)-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid or a derivative thereof and an H2 receptor antagonist antihistamine
CY1306A (en) * 1980-10-01 1985-12-06 Glaxo Group Ltd Aminoalkyl furan derivative
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
EP0077529B1 (de) * 1981-10-16 1985-07-17 Sanol Schwarz GmbH Arzneimittelformulierung
JPS58174308A (ja) * 1982-04-06 1983-10-13 Fujimoto Seiyaku Kk レクタルカプセル坐剤
CA1211374A (en) * 1982-05-14 1986-09-16 Eszter Cholnoky Pharmaceutical compositions containing more active ingredients
DE3237814A1 (de) * 1982-10-12 1984-04-12 Warner-Lambert Co., 07950 Morris Plains, N.J. Wasserfreie emulsionen und verwendung derselben
DE3490358T1 (de) * 1983-08-01 1985-10-31 R.P. Scherer Corp., Troy, Mich. Retard-Verfahren und -erzeugnis
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
GB8426738D0 (en) * 1984-10-23 1984-11-28 Scras Pyridine derivatives
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
JPH07549B2 (ja) * 1986-07-03 1995-01-11 ゼリア新薬工業株式会社 軟カプセル充填用組成物
DE3629386A1 (de) * 1986-08-29 1988-03-03 Scherer Gmbh R P Gelatinekapseln und verfahren zu ihrer herstellung
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
BE1002406A5 (fr) * 1988-09-20 1991-01-29 Glaxo Group Ltd Compositions pharmaceutiques.

Also Published As

Publication number Publication date
ZW1790A1 (en) 1991-10-16
JP2856817B2 (ja) 1999-02-10
IT1240768B (it) 1993-12-17
CY1734A (en) 1994-05-06
NL193267B (nl) 1999-01-04
SE512412C2 (sv) 2000-03-13
IT9047659A0 (it) 1990-02-22
US5028432A (en) 1991-07-02
CA2010692C (en) 1995-12-12
AU5007390A (en) 1990-08-30
AT401727B (de) 1996-11-25
GB9004016D0 (en) 1990-04-18
DE4005650A1 (de) 1990-09-06
IE63179B1 (en) 1995-03-22
ZA901348B (en) 1991-03-27
FR2643263B1 (fr) 1994-09-16
DK48090D0 (da) 1990-02-22
FR2643263A1 (fr) 1990-08-24
NZ232642A (en) 1992-07-28
DE4005650C2 (de) 1999-03-25
ATA42190A (de) 1996-04-15
LU87681A1 (fr) 1991-10-08
HK89493A (en) 1993-09-03
CH680567A5 (ko) 1992-09-30
BE1003123A3 (fr) 1991-12-03
NL9000428A (nl) 1990-09-17
IT9047659A1 (it) 1991-08-22
IL93490A (en) 1994-07-31
GB8904182D0 (en) 1989-04-05
SE9000625L (sv) 1990-08-24
IL93490A0 (en) 1990-11-29
GB2229094B (en) 1993-01-06
SE9000625D0 (sv) 1990-02-22
DK170209B1 (da) 1995-06-19
AU629303B2 (en) 1992-10-01
DK48090A (da) 1990-08-24
KR940006271B1 (ko) 1994-07-14
JPH03200728A (ja) 1991-09-02
PH26972A (en) 1992-12-28
HU211930A9 (en) 1996-01-29
CA2010692A1 (en) 1990-08-23
GB2229094A (en) 1990-09-19
NL193267C (nl) 1999-05-06
SA90100287B1 (ar) 1999-08-15
IE900651L (en) 1990-08-23

Similar Documents

Publication Publication Date Title
KR900012612A (ko) 제약 조성물
ATE117547T1 (de) Orale lipidarzneiform.
BR9811058A (pt) Formulação auto-emulsificante para compostos lipofìlicos
PT1037666E (pt) Metodo para aumentar a absorcao e o transporte de compostos lipidicos soluveis usando gliceridos estruturados
EA200300634A1 (ru) Фармацевтическая композиция, содержащая действующее вещество, диспергированное в матрице
CA2376202A1 (en) Novel preparation and administration form comprising an acid-labile active compound
KR880001301A (ko) 지속성 약품 제제
IT1187687B (it) Composizioni farmaceutiche contenenti come principi attivi flavanolignani e fosfolipidi
HUP9903855A2 (hu) Orális adagolásra való valproesavat tartalmazó gyógyszerészeti mikrogömbök
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
MY138975A (en) Novel preparation and administration form comprising an acid-labile active compound
ES2019595B3 (es) Empleo de glicofurol para licuacion de preparaciones medicas, para el llenado en capsulas de gelatina blanda
ES2051827T3 (es) Una composicion farmaceutica que contiene aceite de ricino polietoxilado.
KR890003388A (ko) 경구투여용 에리스로 마이신 조성물
CO4970832A1 (es) Nuevas formulaciones y procesos para su fabricacion
KR950030831A (ko) 물고기 사료
WO1999039682A3 (en) Lipid mixtures and their use
KR890011594A (ko) 4-아로일이미다졸-2-온의 제약 조성물
SE8301565L (sv) Oljeloslig komposition innehallande fettloslig vitamin
KR900701254A (ko) 정제 가능한 제제 및 이것으로 만들어진 정제
KR950703338A (ko) 3-치환된 2-옥스인돌-1-카복스아미드 약학 조성물(3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions)
US5482973A (en) Suppository preparation
KR960040167A (ko) 유지의 산화방지 조성물
BR9808324A (pt) Composições farmacêuticas
JPS55105623A (en) Preparation of filler for hard capsules

Legal Events

Date Code Title Description
AMND Amendment
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090630

Year of fee payment: 16

EXPY Expiration of term